Cell thawer, GCCT-2.0 water-free significantly reduces the apoptosis rate of cells after thawing
JC-1 is an ideal fluorescent probe widely used for detecting mitochondrial membrane potential ∆Ψm. It can detect the membrane potential of cells, tissues, or purified mitochondria. When the mitochondrial membrane potential is high, JC-1 aggregates in the matrix of mitochondria, forming polymers (J-aggregates) that can produce red fluorescence; When the mitochondrial membrane potential is low, JC-1 cannot aggregate in the mitochondrial matrix. At this time, JC-1 is a monomer that can produce green fluorescence. This makes it very convenient to detect changes in mitochondrial membrane potential through changes in fluorescence color. The relative ratio of red green fluorescence is commonly used to measure the depolarization of mitochondria.
The decrease in mitochondrial membrane potential is a landmark in the early stages of cell apoptosis. The decrease in cell membrane potential can be easily detected by the transition of JC-1 from red fluorescence to green fluorescence, and the transition of JC-1 from red fluorescence to green fluorescence can also be used as a detection indicator for early cell apoptosis.
From the above figures, it can be seen that compared with the cells thawed by water bath, the decrease in mitochondrial membrane potential and significant reduction in cell apoptosis were observed in the cells thawed by the Grocellbio GCCT-2.0 water-free cell thawer(PTC in above figures), which is superior to the water bath(Non-PTC in above figures)
Grocellbio:Innovating the Future of Cell Thawing
Your Partner for Safe, Automated and Standardized Thawing
Clinical project using Grocellbio cell thawing devices in the process which were accepted or approved by the FDA
STRATEGIC PARTNER
|
Clinical Study |
ClinicalTrials.gov ID |
Drug Type |
FDA website link |
|
Phase I Clinical Study of BR105 Injection (BR105-I) |
NCT05351697 |
mAb |
https://clinicaltrials.gov/study/NCT05351697?term=BR105&rank=1 |
|
Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis |
NCT04728360 |
Biosimilar
|
https://clinicaltrials.gov/study/NCT04728360?term=BAT2206&rank=2 |
|
Study to Compare the Efficacy and Safety of F-627 and GRAN |
NCT04174599 |
G-CSF |
https://clinicaltrials.gov/study/NCT04174599?term=evive&page=1&rank=2 |
|
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas |
NCT06544720 |
CAR-T |
https://clinicaltrials.gov/study/NCT06544720?term=SCG142&rank=1 |
|
An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency. |
NCT05765981 |
Gene Therapy |
https://clinicaltrials.gov/study/NCT05765981?term=VGN-R09b&rank=1 |